



Final Appraisal Recommendation
Advice Number: 1521 – November 2021

Glecaprevir/pibrentasvir (Maviret®)
50 mg/20 mg coated granules in sachet

Submission by AbbVie Ltd

Recommendation of AWMSG

Glecaprevir/pibrentasvir (Maviret®) granules are recommended as an option for use within NHS Wales, for the treatment of chronic hepatitis C virus (HCV) infection in children aged 3 years to < 12 years, and glecaprevir/pibrentasvir (Maviret®) tablets are recommended as an option for use within NHS Wales for those aged 12 years to less than 18 years.

Additional note(s):

- This advice incorporates and replaces the AWMSG recommendation for glecaprevir/pibrentasvir (Maviret®) for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 years to less than 18 years (advice number 3213, originally published December 2013).
- See NICE guidance for glecaprevir/pibrentasvir (Maviret®) for the treatment of chronic hepatitis C virus (HCV) infection in adults (TA499, originally published January 2018).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference numbers 4917 and 3917), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1521:
Glecaprevir/pibrentasvir (Maviret®) 50 mg/20 mg coated granules in sachet November 2021.

